Puma Biotechnology, Inc. 股票：股价与高管交易 · 美国

Puma Biotechnology, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker PBYI. Headquartered in Los Angeles, California, in the United States, the company focuses on acquiring, developing, and commercializing novel cancer therapeutics. Its strategy is that of a specialty oncology biotech rather than a broad diversified pharmaceutical group: Puma tends to license or in-license assets with clinical precedent, advance them through development, and then build commercial value through focused execution. The company’s current corporate form traces back to 2010, and founder Alan H. Auerbach has remained central to the business since inception. ([pumabiotechnology.com](https://www.pumabiotechnology.com/about/overview.html?utm_source=openai))

Puma’s core commercial asset is NERLYNX® (neratinib), an oral oncology therapy that remains the company’s primary revenue driver. Recent company disclosures show that product revenue is derived overwhelmingly from NERLYNX sales, supplemented by royalty income from select international arrangements. In addition to maintaining the NERLYNX franchise, Puma has added a second growth pillar with alisertib, an asset in-licensed from Takeda in 2022. The drug is now being advanced in clinical programs such as ALISCA™-Breast1 and ALISCA™-Lung1, which target chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer and extensive-stage small cell lung cancer. For investors, that is an important point: Puma remains highly dependent on one marketed product, but it is also working to expand its pipeline and reduce single-asset concentration over time. ([investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025))